NLM001 was initially developed by Takeda and Known as Tak-441.
IT HAS SHOWN IN THE CLINIC A FAVORABLE TOXICITY PROFILE, LINEAR AND DOSE PROPORTIONAL Pharmacokinetic-Pharmacodynamic profile AND EVIDENCE OF PATHWAY INHIBITION IN SERIAL SKIN BIOPSIES.
In Cancer
Anti-tumor activity has been shown in different mouse tumor models, causing tumor regression in medulloblastoma, even in tumors that were resistant to other hedgehog inhibitors.
During the Phase I clinical trial, NLM001 was well tolerated in the doses tested and showed preliminary antitumoral activity.
NLM-001 is now in a Phase Ib/IIa clinical trial in pancreatic cancer in combination with chemotherapy and immunotherpay.
in fibrosis
NLM-001 has shown significant antifibrosis activity in SEVERAL MOUSE MODELS INCLUDING PULMONARY, liver and skin FIBROSIS.
